MedinCell S.A.

MEDCL

FR0004065605

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-02-06 am EST			5-day change	1st Jan Change
23.76 ^EUR	+1.89%		+5.32%	-5.71%

Jan. 29	Modest Recovery for Medincell Following Sharp Decline
Jan. 28	Medincell S.A. Reports Sales Results for the Fourth Quarter and Full 2025	CI

MedinCell S.A. Appoints Christophe Douat as Chief Executive Officer

Published on 09/13/2024 at 02:00 am EDT

S&P Capital IQ

MEDINCELL S.A.

+1.89%

MedinCell S.A. at its Ordinary Annual and Extraordinary General Meeting held on September 12, 2024, the Board of Directors appointed Christophe Douat as Chief Executive Officer (previously Chairman of the Executive Board).

Latest news about MedinCell S.A.

Jan. 29	Modest Recovery for Medincell Following Sharp Decline
Jan. 28	Medincell S.A. Reports Sales Results for the Fourth Quarter and Full 2025	CI
Jan. 28	Medincell S.A. Provides Revenue Guidance for the Year 2026	CI
Jan. 28	MedinCell says Uzedy net sales increased 63% to $191 million in 2025	RE
Jan. 26	Polar Capital Exceeds 5% Stake in MedinCell
Jan. 19	MedinCell S.A.: One to Watch Today
Jan. 16	MedinCell, Biggest Gainer on the SBF 120 at Friday's Close, January 16, 2026
Jan. 16	Medincell Buoyed by Positive Oddo BHF Rating
Dec. 10	Medincell Narrows Operating Loss in First Half
Dec. 10	MedinCell Says Partner Filed US FDA Application for Once-monthly Schizophrenia Treatment	MT
Dec. 10	French and Benelux stocks-Factors to watch	RE
Dec. 09	MedinCell S.A., H1 2026 Earnings Call, Dec 09, 2025
Dec. 09	Teva Pharmaceuticals Announces the New Drug Application	CI
Dec. 09	Medincell H1 revenues EUR 11.6 mln	RE
Dec. 09	Medincell Files for FDA Approval of Olanzapine LAI
Dec. 09	Teva Pharmaceuticals Submits FDA Application for Monthly Schizophrenia Treatment	MT
Dec. 08	MedinCell S.A. Reports Earnings Results for the Half Year Ended September 30, 2025	CI
Dec. 07	Earnings calendar for week of December 8-12, 2025: Oracle, Adobe, Broadcom a trio to watch
Nov. 25	Medincell Shares Rise Following $3 Million Grant from Gates Foundation
Nov. 24	Medincell SA receives $3 million grant from Gates Foundation to fight malaria	RE
Nov. 11	Paris Surges Again While Wall Street Hesitates
Nov. 11	CAC40: Europe's Powerhouse Surges 2.6% in 48 Hours, Outperforming the Nasdaq
Nov. 11	CAC 40 Boosted by Luxury Sector and US Market Rebound
Nov. 11	MedinCell Appoints Chief Strategy Officer for US Finance	MT
Nov. 11	Medincell appoints chief strategy officer, US finance

Chart MedinCell S.A.

Duration

Period

MEDCL: Dynamic Chart

Company Profile

MedinCell S.A. is a pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas, combining its proprietary BEPO® technology with active ingredients already known and marketed. The BEPO® technology allows the regular delivery of a drug at optimal therapeutic dose for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. The first treatment based on BEPO® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name SteadyTeqTM). As of March 31, 2025, the company had a portfolio of 2 products in phase III clinical development and 3 products in preclinical development.

Employees

145

Sector

Pharmaceuticals

Calendar

Jun. 15 - Q4 2026 Earnings Release (Projected)

More about the company